Analysts expect that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce $1.55 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings. The highest sales estimate is $3.50 million and the lowest is $730,000.00. AcelRx Pharmaceuticals posted sales of $820,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 89%. The company is expected to issue its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $8.57 million for the current fiscal year, with estimates ranging from $6.41 million to $11.90 million. For the next fiscal year, analysts expect that the company will report sales of $35.43 million, with estimates ranging from $29.00 million to $47.20 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.85 million.
ACRX has been the topic of several research analyst reports. BidaskClub upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Thursday, March 28th. B. Riley assumed coverage on shares of AcelRx Pharmaceuticals in a research note on Wednesday, April 24th. They set a “buy” rating and a $6.50 price target on the stock. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a research note on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. AcelRx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $7.47.
Large investors have recently modified their holdings of the business. Weiss Asset Management LP purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $113,000. Resources Investment Advisors Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $34,000. Ahrens Investment Partners LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $108,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $140,000. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $521,000. Institutional investors own 15.53% of the company’s stock.
ACRX traded down $0.08 on Thursday, hitting $2.10. The company had a trading volume of 949,200 shares, compared to its average volume of 1,852,383. The stock has a market cap of $169.66 million, a price-to-earnings ratio of -2.59 and a beta of 2.41. AcelRx Pharmaceuticals has a 1 year low of $1.99 and a 1 year high of $5.05. The stock’s fifty day simple moving average is $2.64. The company has a debt-to-equity ratio of 0.79, a quick ratio of 4.91 and a current ratio of 5.03.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Featured Story: What is Forex?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.